Medical Reports First Quarter 2022 Financial Results and
|●||Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine|
|●||Increased commercial activity in the U.S. and globally with several new ProSense® System installations during Q1|
|●||Resumption of in-person medical conferences and practitioner site visits boosts ProSense® hands-on demos, trainings, and sales opportunities|
|●||American Society of Breast Surgeons’ former President presented IceCure’s ICE3 trial clinical publication in her speech “Best Papers of 2021” at ASBrS following a thorough literature review of thousands of breast cancer articles published yearly|
CAESAREA, Israel, May 18, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal (“ProSense”), today reported financial results as of and for the quarter ended March 31, 2022 and operational highlights.
Q1 2022 Operational and Financial Highlights
|●||Revenues: Revenues for the first quarter of 2022 were approximately $0.75 million, 48% lower than approximately $1.4 million in the same period last year due to lower revenue recognition from its distribution agreements with Terumo for the commercialization of ProSense® to treat malignant breast tumors in Japan, Singapore, and Thailand as recorded in the first quarter of 2021, and due to lower sales in Asia impacted by COVID surges and associated restrictions on commercial activity, partially offset by higher sales in the U.S. The Company expects that quarter-over-quarter revenue may vary in the foreseeable future.|
|●||Increased Commercial Activity: With travel restrictions relaxing at the end of 2021, during Q1 2022 several ProSense® Systems were installed at new sites in the U.S. and around the globe including a ProSense® System that was donated to Tata Memorial Hospital in Mumbai by the Israeli General Consulate of Mumbai in collaboration with the Health Ministry of the Government of Maharashtra and the Israel Trade & Economic Mission to Mumbai. IceCure has scheduled and is now able to conduct more on-site support and training with partners and customers around the globe.|
|●||FDA Filing for Breast Cancer: Working toward U.S. Food and Drug Administration (FDA) approval for ProSense® in early-stage breast cancer, IceCure filed its pre-submission package with the FDA in November 2021 and continued to work on its full submission during Q1 2022. IceCure plans to suggest a De Novo classification, including a request for a sprint discussion under FDA procedures. The proposed intended use is for early-stage breast cancer patients at high risk from surgery.|
|●||R&D and Marketing: IceCure accelerated its next-generation single-probe system development and its clinical, regulatory, and commercial activities in the U.S. and globally. As of March 31, 2022, ProSense® has regulatory approvals and/or has a commercial presence in 20 countries.|
|●||SIO Conference: IceCure attended the Society of Interventional Oncology (SIO) 2022 Annual Scientific Meeting in San Francisco and hosted a symposium moderated by Dr. Jack Jennings on the value of liquid nitrogen based cryoablation systems for optimal tumor destruction.|
Other Recent Highlights
|●||ASBrS Conference: ICE3 Trial Selected as one of “Best Papers of 2021” for Annual Presentation from Thousands of Articles Published Annually – At the 23rd Annual Meeting of the American Society of Breast Surgeons (ASBrS) in April, IceCure’s publication titled “Cryoablation without Excision for Low-Risk Early-Stage Breast cancer: 3-Year Analysis of ipsilateral Breast Tumor Recurrence in the ICE3 Trial” published in the Annals of Surgical Oncology was selected by past ASBrS president, Helen Pass, MD, Co-Director of the Stamford Health Breast Center, Chief of Breast Surgery at Stamford Hospital, and Clinical Professor of Surgery at Columbia University, for her annual presentation following a comprehensive literature review. Dr. Pass’ presentation was made before a large audience of breast surgeons and related medical professionals attending the conference in-person and online.|
|●||ECIO Conference: At the European Conference on Interventional Oncology (ECIO) in April, IceCure’s ICE3 breast cancer trial interim results, originally published on April 29, 2021, were presented by Dr. Kenneth R. Tomkovich, the study’s Co-Primary Investigator. Hands-on training sessions with the ProSense® System were provided by IceCure and physicians well-experienced with the system. IceCure also hosted a well-attended Symposium moderated by Professor Franco Orsi and other physicians, demonstrating their results and experience with the ProSense® System for various applications.|
“With the reopening of global travel and healthcare systems’ return to relative normalcy throughout most of the world, during the first quarter of 2022 we significantly increased our activity, getting ProSense® in front of more doctors who can purchase and use it to improve patient outcomes,” stated IceCure CEO Eyal Shamir. “We were particularly pleased that our ICE3 clinical trial publication was chosen as one of the Best Papers of 2021 by the American Association of Breast Cancer Surgeons, a highly regarded and influential organization that sets the treatment guidelines for breast cancer in the U.S.”
Financial Results as of and for the Three Months Ended March 31, 2022
For the three months ended March 31, 2022, revenue decreased by 48% to approximately $0.75 million, compared to approximately $1.4 million for the three months ended March 31, 2021. The decrease is due to decreased revenue recognition of approximately $0.4 million from the distribution agreement with Terumo and a decrease in sales in Asia, partially offset by an increase in sales in the U.S.
Gross profit was approximately $0.43 million for the three months ended March 31, 2022, compared to approximately $0.94 million for the three months ended March 31, 2021. Gross margin was approximately 58% for the three month period ended March 31, 2022, compared to approximately 65% for the three months ended March 31, 2021. The decrease in gross margin compared to the same period last year is mostly attributable to the decrease in revenue recognition from the Terumo distribution agreement.
Research and development expenses for the three months ended March 31, 2022 were approximately $2.4 million compared to approximately $1.1 million for the three months ended March 31, 2021. The increase is attributed to the acceleration in the development of IceCure’s next-generation single-probe system and clinical and regulatory activities.
Sales and marketing and general and administrative expenses, in the aggregate, for the three months ended March 31, 2022 were $2.5 million compared to approximately $1 million for the three months ended March 31, 2021. The increase is attributed to the Company’s expanding commercialization efforts and to increased Nasdaq listing related expenses.
Total operating expenses for the three months ended March 31, 2022 were approximately $4.9 million compared to $2.1 million for the three months March 31, 2021. The increase in operating expenses is attributable to increased development, commercialization, and Nasdaq listing related activities.
As a result of lower revenue and increased operation activities, net loss reported for the three month period ended March 31, 2022 increased to approximately $4.4 million, or $0.12 per share, compared with a net loss of approximately $1.4 million, or $0.07 per share, for the same period last year.
As of March 31, 2022, the Company had cash and cash equivalents of approximately $22.4 million, compared with approximately $25.6 million as of December 31, 2021.
Conference Call Dial-in Info:
Wednesday, May 18, 2022 at 8:30 am ET
A replay of the conference call will be available on IceCure’s website at: https://ir.icecure-medical.com/news-events/events-presentations
About IceCure Medical
Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses pursuit of regulatory approvals and FDA review, strategic plans, commercial growth, expansion of clinical applications with its minimally-invasive cryoablation technology, advancing regulatory and commercial strategies and expected quarter-over-quarter revenue variations for future periods. Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
of December 31,|
|U.S. dollars in thousands|
|Cash and cash equivalents||22,355||25,621|
|Trade accounts receivables||446||456|
|Prepaid expenses and other receivables||1,562||2,290|
|Total current assets||26,687||30,322|
|Prepaid expenses and other long-term assets||333||333|
|Property and equipment, net||805||713|
|Total non-current assets||2,022||1,959|
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Trade accounts payable||670||881|
|Other current liabilities||4,046||2,915|
|Total current liabilities||4,946||4,020|
|Long-term lease liabilities||617||685|
|Other long-term liabilities||185||618|
|Total non-current liabilities||802||1,303|
|Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and outstanding: 35,780,335 shares as of March 31, 2022 and December 31, 2021, respectively|
|Pre-funded warrants to ordinary shares, Issued and outstanding: 1,034,000 Pre-funded warrants and zero Pre-funded warrants as of March 31, 2022 and December 31, 2021, respectively||-||-|
|Additional paid-in capital||85,839||85,389|
|Total shareholders’ equity||22,961||26,958|
|TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY||28,709||32,281|
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
dollars in thousands
(except per share data)
|Cost of revenues||313||497|
|Research and development expenses||2,394||1,144|
|Sales and marketing expenses||747||298|
|General and administrative expenses||1,718||690|
|Financial expenses, net||22||178|
|Net loss and comprehensive loss||4,447||1,371|
|Basic and diluted net loss per share||0.12||0.07|
|Weighted average number of shares outstanding used in computing basic and diluted loss per share||36,814,335||20,739,571|
ICECURE MEDICAL LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
Three months ended
|U.S. dollars in thousands|
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Exchange rate changes in cash and cash equivalents and short time deposits||62||206|
|Changes in assets and liabilities:|
|Decrease (increase) in trade accounts receivables||10||(156||)|
|Decrease (increase) in prepaid expenses and other receivables||728||(109||)|
|Increase in inventory||(369||)||(137||)|
|Decrease in right of use assets||29||43|
|Increase (decrease) in trade accounts payable||(211||)||20|
|Decrease in lease liabilities||(62||)||(33||)|
|Increase (decrease) in other current liabilities||1,131||(252||)|
|Decrease in other long-term liabilities||(433||)||(174||)|
|Net cash used in operating activities||(3,060||)||(1,843||)|
|Cash flows from investing activities|
|Investment of deposits||-||4,621|
|Purchase of property and equipment||(144||)||(69||)|
|Net cash provided by (used in) investing activities||(144||)||4,552|
|Cash flows from financing activities|
|Issuance of ordinary shares, net of issuance cost||-||8,880|
|Exercise of options to ordinary shares||-||52|
|Net cash provided by financing activities||-||8,932|
|Increase (decrease) in cash and cash equivalents||(3,204||)||11,641|
|Cash and cash equivalents at beginning of the year||25,621||3,502|
|Effect of exchange rate fluctuations on balances of cash and cash equivalents||(62||)||(158||)|
|Cash and cash equivalents at end of period||22,355||14,985|